HOMEVULNERABILITIESCVE-2018-14789
MEDIUM

CVE-2018-14789

CWE-428Published: August 22, 2018· Updated: Jun 17, 2026

6.7
CVSS v3.1

Official Description

In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 3.1 or prior and Xcelera Version 4.1 or prior), an unquoted search path or element vulnerability has been identified, which may allow an attacker to execute arbitrary code and escalate their level of privileges.

NVD Source

Technical Analysis

CVE-2018-14789 requires local access, meaning attackers must already have a foothold on the target system.

Exploitation requires high privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), availability disruption (denial of service), with a CVSS base score of 6.7.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorLocal
Attack ComplexityLow
Privileges Req.High
User InteractionNone
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityHigh
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H

Affected Vendors & Products

philips2 product(s)
intellispace cardiovascularxcelera
Source: NVD CPE · 2 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (4)

Quick Facts

CVE IDCVE-2018-14789
CVSS Score6.7 / 10
SeverityMEDIUM
WeaknessCWE-428
CISA KEVNo
Affected1 vendor(s)
PublishedAug 22, 2018

Related CVEs (CWE-428)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2018-14789 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.